M&A and equity raisings

6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

US deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

73 deals · US$14bndisclosed · Biotech · Clear

Columns
M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
May 2025 Chimeric Therapeutics ––PlacementAnnounced4.2Biotech+2 PAC Partners (lead manager)Taylor Collison (lead manager)
Sep 2025 Neurizon Therapeutics ––PlacementCompleted3.3Biotech+1 Petra Capital (lead manager)
Dec 2025 Apimeds Pharmaceuticals US ––ConvertibleCompleted10.9Pharma+1 Nelson Mullins Riley & Scarborough (issuer)EF Hutton (lead manager)
Jan 2026 Suzhou Ribo Life Science Co. ––IPOListed–Biotech+2 Kirkland & Ellis (issuer)CICC (lead manager)Citi (lead manager)
Jan 2026 Aktis Oncology ––IPOListed317.7Biotech+2 Paul Hastings (issuer)Goodwin (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Davis Polk (lead manager)
Jan 2026 AdAlta ––PlacementCompleted0.8Biotech+1 Sixty Two Capital (lead manager)
Jan 2026 Polaryx Therapeutics ––Direct listingCompleted–Biotech+1 Maxim Group (issuer)Gibson Dunn (issuer)Brownstein Hyatt Farber Schreck (issuer)
Feb 2026 Perspective Therapeutics ––Follow-on offeringAnnounced175.0Radiopharmaceuticals+2 Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager)LifeSci Capital (lead manager)
Feb 2026 Veradermics ––IPOAnnounced256.3Dermatology+2 Ropes & Gray (issuer)Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Cantor Fitzgerald (lead manager)Cooley (lead manager)
Feb 2026 Eikon Therapeutics ––IPOAnnounced381.2Oncology+1 Covington & Burling (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)BofA Securities (lead manager)Cantor Fitzgerald (lead manager)Mizuho Securities (lead manager)Davis Polk (lead manager)
Feb 2026 Agomab Therapeutics NV ––IPOAnnounced200.0Biotech+2 Goodwin (issuer)Baker McKenzie (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)Leerink Partners (lead manager)Van Lanschot Kempen (lead manager)Davis Polk (lead manager)Clifford Chance (lead manager)
Feb 2026 Liminatus Pharma ––Follow-on offeringAnnounced4.0Biotech+2 Loeb & Loeb (issuer)Maxim Group (lead manager)Lucosky Brookman (lead manager)
Feb 2026 Sensei Biotherapeutics ––PlacementPending200.0Biotech+2 Cantor Fitzgerald (issuer)Citi (issuer)Sidley Austin (issuer)Leerink Partners (lead manager)
Feb 2026 Generate Biomedicines ––IPOListed400.0Biotech+2 Goodwin (issuer)Goldman Sachs (lead manager)Morgan Stanley (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager)
Mar 2026 Candid Therapeutics ––PlacementPending505.0Biotech+1 Cooley (issuer)Jefferies (lead manager)BofA Securities (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager)
Mar 2026 Imugene ––PlacementCompleted14.0Biotech+1 McCullough Robertson (issuer)E&P Capital (lead manager)Barrenjoey (lead manager)Bell Potter (lead manager)
Mar 2026 Pulmatrix ––PlacementAnnounced19.0Biotech Palladium Capital Group (lead manager)
Apr 2026 Korsana Biosciences ––PlacementAnnounced380.0Biotech+1 Cooley (lead manager)
Apr 2026 Obsidian Therapeutics ––PlacementCompleted350.0Biotech+2 GoodwinSidley Austin (issuer)Leerink Partners (lead manager)TD Securities (lead manager)Piper Sandler (lead manager)William Blair (lead manager)LifeSci Capital (lead manager)Mintz (lead manager)
Apr 2026 Kailera Therapeutics ––IPOAnnounced625.0Biotech+1 Latham & Watkins (issuer)William Blair (lead manager)J.P. Morgan (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Evercore (lead manager)Paul Hastings (lead manager)
Apr 2026 Opus Genetics ––PlacementAnnounced5.0Biotech+1 Sidley Austin (issuer)
Apr 2026 Avalyn Pharma ––IPOListed300.0Biotech+2 Goodwin (issuer)Morgan Stanley (lead manager)Jefferies (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)Davis Polk (lead manager)
Apr 2026 Hemab Therapeutics Holdings ––IPOAnnounced301.5Biotech+1 WilmerHale (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Wedbush Securities (lead manager)Goodwin (lead manager)
Apr 2026 Seaport Therapeutics ––IPOAnnounced254.9Biotech+1 Goodwin (issuer)Goldman Sachs (lead manager)J.P. Morgan (lead manager)Leerink Partners (lead manager)Citi (lead manager)Stifel (lead manager)Latham & Watkins (lead manager)
May 2026 Odyssey Therapeutics ––IPOAnnounced279.0Biotech+1 Covington & Burling (issuer)J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Wedbush Securities (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager)
May 2026 Odyssey Therapeutics ––PlacementPending25.0Biotech+1 J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Wedbush Securities (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager)
May 2026 IMPACT Therapeutics ––IPOListed–Biotech+2 Cooley (issuer)Goldman Sachs (lead manager)CICC (lead manager)Kirkland & Ellis (lead manager)
May 2026 METiS TechBio ––IPOAnnounced–Biotech+2 Davis Polk (issuer)
May 2026 Quince Therapeutics ––PlacementAnnounced115.0Biotech+2 EvercoreCantor FitzgeraldLifeSci Capital (lead manager)Gibson Dunn (lead manager)
May 2026 Mentari Therapeutics ––PlacementAnnounced290.0Biotech+1 Gibson Dunn (issuer)Cooley (lead manager)Jefferies (lead manager)TD Securities (lead manager)Stifel (lead manager)Guggenheim Securities (lead manager)Wedbush Securities (lead manager)
May 2026 Optimi Health Corp. ––Follow-on offeringAnnounced15.0Biotech+2 Norton Rose Fulbright (issuer)Joseph Gunnar & Co. (lead manager)Cozen O'Connor (lead manager)
Jun 2026 Avenzo Therapeutics ––PlacementPending215.0Biotech+2 Leerink Partners (lead manager)Goldman Sachs (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Mintz (lead manager)
Jun 2026 Parabilis Medicines ––IPOListed670.0Biotech+2 Goodwin (issuer)Leerink Partners (lead manager)BofA Securities (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)Covington & Burling (lead manager)
Jun 2026 Adial Pharmaceuticals ––PlacementPending32.0Biotech+1 TD Securities (issuer)Lucid Capital Markets (lead manager)
Jun 2026 Parabilis Medicines ––PlacementCompleted75.0Biotech+1 Goodwin (issuer)
Jun 2026 Kardigan ––IPOListed400.0Biotech+2 Goodwin (issuer)J.P. Morgan (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Latham & Watkins (lead manager)
Jun 2026 HJ Science Co. ––IPOListed–Biotech+1 Sidley Austin (issuer)CITIC CLSA (lead manager)
Jun 2026 Remix Therapeutics ––PlacementPending100.0Biotech+2 Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Cooley (lead manager)
Jun 2026 Alebund Pharmaceuticals (Jiangsu) ––IPOListed–Biotech+1 Jefferies (lead manager)BofA Securities (lead manager)Huatai Securities (lead manager)Davis Polk (issuer)Kirkland & Ellis (lead manager)CITIC CLSA (lead manager)BOCI (lead manager)
Jun 2026 JATT II Acquisition Corp ––PlacementAnnounced225.0Biotech+1 Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)LifeSci Capital (lead manager)Davis Polk (lead manager)
Jul 2026 BridgeBio Pharma ––PlacementAnnounced1,000.0Biotech+1 EvercoreSullivan & CromwellMintzGibson DunnLatham & Watkins (issuer)
Jul 2026 Avere Therapeutics ––PlacementAnnounced320.0Biotech+1 Sullivan & CromwellGibson Dunn (issuer)Cooley (lead manager)Jefferies (lead manager)Wedbush Securities (lead manager)
Jul 2026 Jasper Therapeutics ––PlacementAnnounced132.0Biotech+1 Piper Sandler (lead manager)LifeSci Capital (lead manager)
Jul 2026 Codexis ––Follow-on offeringCompleted–Biotech+1 Piper Sandler (lead manager)
Jul 2026 Scancell Holdings ––PlacementAnnounced54.1Biotech+1 Cooley (issuer)Leerink Partners (lead manager)TD Securities (lead manager)H.C. Wainwright & Co. (lead manager)Mintz (lead manager)Panmure Liberum (lead manager)
Jul 2026 Scribe Therapeutics ––IPOListed128.7Biotech+1 Fenwick & West (issuer)Leerink Partners (lead manager)Goldman Sachs (lead manager)Guggenheim Securities (lead manager)Wells Fargo Securities (lead manager)Latham & Watkins (lead manager)
Jul 2026 Research Alliance Corporation III ––PlacementAnnounced100.0Biotech+2 Leerink Partners (lead manager)UBS (lead manager)Wells Fargo Securities (lead manager)LifeSci Capital (lead manager)Kirkland & Ellis (lead manager)
Jul 2026 Caldera Therapeutics ––PlacementAnnounced278.0Biotech+1 Jefferies (lead manager)TD Securities (lead manager)Guggenheim Securities (lead manager)UBS (lead manager)LifeSci Capital (lead manager)Cooley (lead manager)
Jul 2026 Inovio Pharmaceuticals ––Follow-on offeringCompleted–Biotech+1 Piper Sandler (issuer)
Jul 2026 Processa Pharmaceuticals ––PlacementAnnounced200.0Biotech+1 Leerink Partners (lead manager)Evercore (lead manager)UBS (lead manager)Wells Fargo Securities (lead manager)Mintz (lead manager)

Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.